New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 12, 2014
07:15 EDTTKMR, GSK, NNVC, BCRXWHO says ethical to offer unproven interventions in light of Ebola outbreak
The World Health Organization issued a statement that read in part: "West Africa is experiencing the largest, most severe and most complex outbreak of Ebola virus disease in history. Ebola outbreaks can be contained using available interventions like early detection and isolation, contact tracing and monitoring, and adherence to rigorous procedures of infection control. However, a specific treatment or vaccine would be a potent asset to counter the virus...In the particular circumstances of this outbreak, and provided certain conditions are met, the panel reached consensus that it is ethical to offer unproven interventions with as yet unknown efficacy and adverse effects, as potential treatment or prevention." Publicly traded companies that have confirmed development activities on Ebola treatments include Tekmira Pharmaceuticals (TKMR), GlaxoSmithKline (GSK), NanoViricides (NNVC) and BioCryst (BCRX). Reference Link
News For TKMR;GSK;NNVC;BCRX From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | all recent news | >>
October 17, 2014
14:50 EDTBCRX, TKMR, GSKBARDA asks labs to ramp up Zmapp production, Reuters says
Subscribe for More Information
11:17 EDTGSKGSK says Ebola vaccine too late for current epidemic, BBC reports
Subscribe for More Information
09:46 EDTTKMR, BCRXSarepta soars after publication of Ebola drug candidate data
Subscribe for More Information
October 15, 2014
15:34 EDTTKMRTekmira TKM-HBN preclinical study shows 'knockdown of HBV surface antigen'
Subscribe for More Information
10:49 EDTTKMR, BCRXEbola linked names rise again amid broader market sell-off
Subscribe for More Information
09:57 EDTTKMRLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
08:58 EDTTKMRTekmira volatility up, 2nd Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 14, 2014
13:09 EDTGSKGlaxoSmithKline seeks binding bids for mature drugs, Reuters reports
Subscribe for More Information
11:23 EDTGSKBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
11:19 EDTBCRX, TKMR, GSKNIH says several potential Ebola treatments under development
Subscribe for More Information
10:12 EDTBCRXBioCryst, Chimerix move higher after mention in NIH director blog post
10:10 EDTTKMR, BCRX, GSKNIH director says supporting BioCryst, Chimerix Ebola treatments
Subscribe for More Information
09:04 EDTBCRX, TKMRChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
05:40 EDTTKMRTekmira partner Alnylam reports positive clinical data for Patisiran study
Tekmira Pharmaceuticals (TKMR) reported that Alnylam Pharmaceuticals (ALNY) presented six-month clinical data for the ongoing Patisiran Phase II Open Label Extension, or OLE, study in patients with Familial Amyloidotic Polyneuropathy, or FAP. Patisiran is an RNAi therapeutic targeting transthyretin, or TTR, in development for the treatment of TTR-mediated amyloidosis, or ATTR, which is enabled by Tekmira's lipid nanoparticle, or LNP, technology. Alnylam presented data at the American Neurological Association's 2014 Annual Meeting. Results showed a mean 0.95 point decrease in modified Neuropathy Impairment Score at six months in 19 patients with mNIS+7 data available for the current analysis. This decrease in neuropathy progression compares favorably with the 7 to 10 point increase in mNIS+7 at six months that can be estimated from historical data sets in untreated FAP patients with similar baseline characteristics.
October 13, 2014
07:12 EDTGSK, TKMROligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
07:11 EDTTKMRTekmira volatility elevated, Texas health-care worker tests positive for Ebola
Subscribe for More Information
October 12, 2014
19:26 EDTTKMR, BCRXPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTTKMR, BCRXCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTTKMR, BCRXNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTTKMR, BCRXTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
1 | 2 | 3 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use